EAN2020

Does COVID-19 affect the brain?

1920 1080 Anne Carter, MA (Cantab)

With EAN going virtual this year, the global SARS-CoV2 pandemic was never far from the attendees’ minds. After a brief overview of the putative mechanisms for SARS-CoV2 accessing the brain,…

read more
Brain, Man, Alzheimers

Optimising early diagnosis of Alzheimer’s disease – mission impossible?

1920 1080 Anna Stelling, PhD

Alzheimer’s disease (AD) is a very common malady of the elderly, currently affecting 5.8 million Americans above the age of 65. It accounts for 60–80% of all dementia cases, which…

read more
Sun, ray of light, forest, trees

Siponimod shows promising long-term efficacy in SPMS patients

1920 1280 Anna Stelling, PhD

While researchers are looking at the potential of stem cells in the treatment of multiple sclerosis (MS), novel, promising immune-modulating therapies are being developed. At this year’s virtual EAN Congress,…

read more

Paediatric multiple sclerosis: Adding to our knowledge

1920 1080 Anne Carter, MA (Cantab)

Data suggest that between 2 and 5% of patients with multiple sclerosis (MS) are under 18 years old,1 yet there is only one approved treatment option in this population.2,3 During…

read more
Elderly man on bench by himself outdoors

Why do some glioblastoma patients live longer than others?

1920 1280 Anna Stelling, PhD

Why do some glioblastoma patients live longer than others? Alice Laurenge (Institut du Cerveau et de la Moelle épinière, Sorbonne Université and Hôspitaux universitaire La Pitié Salpêtrière – Charles Foix,…

read more

How to choose antiepileptic drug treatment for refractory epilepsy?

1920 1280 Anne Carter, MA (Cantab)

While most patients with epilepsy respond to one or two drugs, it is estimated that 30% develop drug resistance.1 At EAN 2020, Sylvain Rheims (Department of Functional Neurology and Epileptology,…

read more
Brainwork is supported by unrestricted grants from: